Artiva Biotherapeutics Sets Deadline for 2026 Meeting
at www.tipranks.com (Wed, 22-Jul 5:53 PM)
Artiva’s AlloNK Shines with 71% ACR50 Response in Refractory Rheumatoid Arthritis—FDA RMAT Designation Adds Tailwind
Market Chameleon (Mon, 8-Jun 9:25 AM)
Artiva Biotherapeutics Raises $300 Million in Upsized Offering: Major Healthcare Funds Back Growth Ambitions
Market Chameleon (Fri, 8-May 7:13 AM)
